Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
Bladder Cancer, Urethral Cancer
About this trial
This is an interventional treatment trial for Bladder Cancer focused on measuring stage II bladder cancer, stage III bladder cancer, stage IV bladder cancer, localized transitional cell cancer of the renal pelvis and ureter, regional transitional cell cancer of the renal pelvis and ureter, metastatic transitional cell cancer of the renal pelvis and ureter, anterior urethral cancer, posterior urethral cancer, urethral cancer associated with invasive bladder cancer
Eligibility Criteria
Inclusion Criteria: Patients must have histologically proven urothelial cancer, known or suspected (e.g. by outside evaluation) to be muscle-invasive, and be scheduled for cystoscopy and transurethral biopsy as part of their routine evaluation at M. D. Anderson. Patients must understand the investigational nature of this study and provide written, informed consent. Exclusion Criteria: Patients who are pregnant or lactating are not eligible. Women of child-bearing potential must have a negative pregnancy test before starting therapy. Patients with current symptoms suggestive of clinically significant affective disorder. Patients taking more than physiologic replacement doses of corticosteroids are not eligible.
Sites / Locations
- University of Texas MD Anderson Cancer Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Arm I
Arm II
Arm III
Arm IV
Low-dose interferon alfa subcutaneously (SC) twice daily.
Interferon alfa as in arm I at a higher dose.
Interferon alfa SC once daily.
Interferon alfa as in arm III at a higher dose.